Skip to main
FBRX
FBRX logo

Forte Biosciences (FBRX) Stock Forecast & Price Target

Forte Biosciences (FBRX) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Forte Biosciences is advancing its product candidate, FB-102, through preclinical trials targeting significant autoimmune conditions, positioning itself in a largely untapped market that has substantial growth potential. The company's increasing research and development expenses reflect a commitment to advancing its clinical and manufacturing capabilities, which could lead to competitive advantages in the therapeutic space. Furthermore, the success of competing therapies like PFE’s Litfulo, which has shown significant market growth, indicates a strong demand for effective treatments, suggesting favorable market conditions for Forte's products.

Bears say

Forte Biosciences faces significant market competition from existing and emerging therapies, which could hinder its product candidate FB-102's market penetration and pricing strategies for treating autoimmune conditions. Additionally, the company may encounter delays in clinical development, regulatory approvals, and commercialization timelines, potentially leading to increased costs and prolonged development periods. Furthermore, concerns regarding the effectiveness of FB-102 are highlighted by its low placebo-controlled feedback performance compared to competitors, stemming from a Phase Ib study design that may not adequately demonstrate its therapeutic potential.

Forte Biosciences (FBRX) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Forte Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Forte Biosciences (FBRX) Forecast

Analysts have given Forte Biosciences (FBRX) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Forte Biosciences (FBRX) has a Strong Buy consensus rating as of Nov 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Forte Biosciences (FBRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.